Compare NUVL & TKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUVL | TKR |
|---|---|---|
| Founded | 2017 | 1899 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 7.6B |
| IPO Year | 2021 | 1994 |
| Metric | NUVL | TKR |
|---|---|---|
| Price | $104.60 | $117.83 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 7 |
| Target Price | ★ $134.75 | $118.29 |
| AVG Volume (30 Days) | 506.3K | ★ 808.3K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 1.31% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.40 |
| Revenue | N/A | ★ $80,100,000.00 |
| Revenue This Year | N/A | $4.57 |
| Revenue Next Year | $1,239.49 | $3.97 |
| P/E Ratio | ★ N/A | $84.46 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $70.25 | $67.14 |
| 52 Week High | $113.02 | $123.67 |
| Indicator | NUVL | TKR |
|---|---|---|
| Relative Strength Index (RSI) | 53.04 | 65.03 |
| Support Level | $97.91 | $94.50 |
| Resistance Level | $107.49 | N/A |
| Average True Range (ATR) | 3.83 | 3.62 |
| MACD | -0.18 | 0.94 |
| Stochastic Oscillator | 56.63 | 68.21 |
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
The Timken Co designs and manages a portfolio of engineered bearings and industrial motion products, and provides related services. The various products offered by the company include ball bearings, plain bearings, tapered roller bearings, housed bearings, linear guides, telescopic rails, lubrication systems, agricultural conveyor chains, couplings, brakes, seals, etc. These products are offered through brands like Timken, GGB, Philadelphia Gear, Cone Drive, CGI, and Rollon, among others. The company has two reportable segments: Engineered Bearings, which generates the maximum revenue, and Industrial Motion. Geographically, the company generates maximum revenue from the United States, followed by Europe, Middle East and Africa (EMEA), Asia-Pacific, and the other regions of the Americas.